

News Release



Media Contact:

Lisa Young
Phone: 240.238.4900
lyoung@accelovance.com

Maryland Vaccine Industry Events Capture Accelovance Sponsorship

Rockville, MD – September 28, 2009 – Local industry events focused on vaccine clinical development initiatives for seasonal influenza and H1N1 (swine flu) will receive Accelovance's support through corporate sponsorship. An industry-recognized leading CRO in vaccine clinical research, currently managing multiple H1N1 and seasonal influenza clinical programs, Accelovance has valuable perspective and expertise in this field of research.

Maryland has been a focal point for H1N1 vaccine development; home to the FDA as well as companies such as MedImmune and Novavax who have made headlines with their recent vaccine achievements. "As a CRO who streamlines clinical development activity, we are able to expedite response to public health threats such as the current H1N1 or last year's H5N1 (Bird Flu)," commented Accelovance President and CEO, Stephen J. Trevisan. "These upcoming events allow for all parties to openly discuss vaccine development for infectious diseases that jeopardize public health in the US and abroad."

As anticipation for H1N1 vaccine availability builds, MDBio's BioBreakfast program, "The Swine Flu Pandemic: Public Health Policy and Maryland's Role in Vaccine Development," will be held in Baltimore, Maryland. The event on October 15th proudly welcomes distinguished guests from industry, academia and government agencies to discuss their work and answer questions about a public health concern that has been an area of concern since April of this year.

Weeks later in Bethesda, Maryland, the DIA (Drug Information Association) Global Vaccine Development for World Health Symposium will be held November 3rd and 4th, 2009 at the Bethesda North Marriott Hotel and Conference Center. The event aims to address the expanding need for discussion on regulatory guidelines for the development of vaccines for infectious diseases. Professionals from industry and worldwide regulatory agencies will present the current challenges and solutions around this critical field of global healthcare while also presenting ethical and cultural perspectives.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to vaccine programs. Additionally, the Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Clinical Call Center to develop clinical solutions that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.

For more information, visit the company's website at <http://www.accelovance.com>.